RecruitingPhase 1NCT05131022

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Sponsor

Nurix Therapeutics, Inc.

Enrollment

572 participants

Start Date

Apr 13, 2022

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests NX-5948, a new drug that targets a protein called BTK, in patients with B-cell blood cancers (like certain leukemias and lymphomas) that have come back or stopped responding to other treatments. **You may be eligible if...** - You are 18 or older - You have a relapsed or treatment-resistant B-cell cancer such as CLL, DLBCL, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Waldenström's macroglobulinemia, or primary CNS lymphoma - You have tried at least 2 prior treatments with no remaining standard options **You may NOT be eligible if...** - You have not tried at least 2 prior treatments - Your cancer type is not one of those listed above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNX-5948

Oral NX-5948

Locations(62)

City of Hope

Duarte, California, United States

University of California, San Francisco

San Francisco, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Yale Cancer Center

New Haven, Connecticut, United States

University of Miami

Miami, Florida, United States

Florida Cancer Specialists

Sarasota, Florida, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Northwestern University

Chicago, Illinois, United States

National Institute of Health

Bethesda, Maryland, United States

Cayuga Medical Center

Ithaca, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, United States

MD Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

CHU Angers

Angers, France

Hôpital Avicenne

Bobigny, France

CHU de Nantes

Nantes, France

CHU Bordeaux

Pessac, France

CHU de Poitiers

Poitiers, France

Institut Curie-Site Saint-Cloud

Saint-Cloud, France

CHRU de Nancy

Vandœuvre-lès-Nancy, France

IRCCS - AOU di Bologna

Bologna, Italy

ASST Spedali Civili Brescia

Brescia, Italy

IRCCS Ospedale San Raffaele - Università Vita-Salute San Raffaele di Milano

Milan, Italy

IRCCS Ospedale San Raffaele

Milan, Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS

Rome, Italy

University Medical Center Groningen

Groningen, Netherlands

Radboud University Medical Center

Nijmegen, Netherlands

Erasmus MC

Rotterdam, Netherlands

University Medical Center Utrecht

Utrecht, Netherlands

AidPort sp. Zo.o

Skórzewo, Greater Poland Voivodeship, Poland

Pratia MCM

Krakow, Lesser Poland Voivodeship, Poland

University Clinical Hostpital in Wroclaw

Wroclaw, Lower Silesian Voivodeship, Poland

Pratia MTZ

Warsaw, Masovian Voivodeship, Poland

National Institute of Oncology Warszawa

Warsaw, Masovian Voivodeship, Poland

Pratia Onkologia Katowice

Katowice, Silesian Voivodeship, Poland

Medical University of Lublin

Lublin, Poland

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Clínic de Barcelona

Barcelona, Spain

Hospital Universitario de Cabuenes

Gijón, Spain

Hospital Ramón y Cajal

Madrid, Spain

Hospital Fundación Jimenez Díaz - START Madrid

Madrid, Spain

Universitätsspital Basel

Basel, Switzerland

Istituto Oncologico della Svizzera Italiana

Bellinzona, Switzerland

Inselspital - Universitatsklinik Bern

Bern, Switzerland

Hôpitaux Universitaires de Genève

Geneva, Switzerland

Kantonsspital St.Gallen

Sankt Gallen, Switzerland

University Hospital Zurich

Zurich, Switzerland

The Beatson WOS Cancer Center

Glasgow, Scotland, United Kingdom

St. James Hospital

Leeds, United Kingdom

Clatterbridge Cancer Center NHS Foundation Trust

Liverpool, United Kingdom

St. Bartholomew's Hospital, Barts NHS Trust

London, United Kingdom

Sarah Cannon Research Institute UK

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

University Hospitals Plymouth NHS Trust

Plymouth, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

Royal Marsden NHS Foundation Trust

Sutton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05131022

Related Trials

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

NCT010873331 location

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

NCT072053152 locations

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT057241211 location

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT0722150020 locations

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

NCT070304001 location